Lung Cancer
Lung cancer is a type of cancer that starts in the cells of the lungs. It is the leading cause of cancer-related deaths worldwide. The most common type of lung cancer is non-small cell lung cancer (NSCLC), which accounts for about 85% of all cases. Less common types include small cell lung cancer (SCLC) and carcinoid tumors. Hematology and oncology research in lung cancer focuses on several areas. One of the main areas of research is early detection. Early detection is critical because lung cancer is often diagnosed at an advanced stage when treatment is less effective. Researchers are exploring the use of biomarkers, imaging techniques, and other methods to detect lung cancer at an earlier stage. Another area of research is the development of new treatments for lung cancer. Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Researchers are developing new drugs and therapies that target specific molecular pathways involved in the development and growth of lung cancer cells. Immunotherapy is an exciting area of research in lung cancer. This type of therapy harnesses the power of the immune system to fight cancer cells. Immunotherapy drugs called checkpoint inhibitors have shown promising results in treating lung cancer. Researchers are also exploring the use of combination therapies that combine checkpoint inhibitors with other types of treatments. Overall, hematology and oncology research in lung cancer is aimed at improving outcomes for patients. This includes developing more effective ways to detect and diagnose lung cancer, as well as developing new treatments that are more targeted and personalized. With ongoing research, we hope to improve survival rates and quality of life for those affected by lung cancer.
← Hematology Research and Oncology Research